What is BPC-157?
BPC-157 is a pentadecapeptide composed of 15 amino acids. It is a partial sequence of the body protection compound (BPC) discovered in and isolated from human gastric juice. Structurally stable and highly resistant to gastric acid, BPC-157 has been the subject of extensive pre-clinical research focused on accelerating the healing of various tissues including tendons, muscles, ligaments, and the gastrointestinal tract.
How does BPC-157 work?
BPC-157 functions primarily by upregulating growth factors, particularly Vascular Endothelial Growth Factor (VEGF), which triggers angiogenesis (the formation of new blood vessels). This increased blood flow delivers vital nutrients to damaged tissues. Additionally, it promotes the expression of EGR-1 (Early Growth Response-1) and collagen, which are crucial for cellular migration and tissue reconstruction. It also interacts with the nitric oxide (NO) pathway, helping regulate vascular tone and protect mucosal linings.
Primary Documented Uses
- Accelerating tendon, ligament, and muscle recovery
- Promoting healing of skin wounds, burns, and surgical incisions
- Mitigating gut inflammation and protecting the gastric lining
- Reducing localized systemic inflammation in musculoskeletal injuries
Research Summary
Animal and in-vitro studies show remarkable tissue-healing acceleration. In rodent models, BPC-157 consistently heals Achilles tendons, collateral ligaments, and skeletal muscle transections. Human clinical trials remain extremely limited; however, pre-clinical safety profiles demonstrate low toxicity. Research also highlights strong cytoprotective properties, particularly in protecting the gastric mucosa against NSAID-induced damage and inflammatory bowel disease (IBD) symptoms in animal models.
Legal and Regulatory Status
In January 2025, the FDA placed BPC-157 on the Bulk Drug Substances Category 2 list, effectively restricting 503A compounding pharmacies from preparing it due to safety concerns and a lack of clinical trial data. It is currently classified as a 'research chemical' and is not approved for human clinical use, though it remains widely studied in pre-clinical settings.
Frequently Asked Questions
What is BPC-157?
BPC-157 is A synthetic peptide derived from a protective protein found in human gastric juice, widely researched for tissue healing and gut health.
How does BPC-157 work?
BPC-157 functions primarily by upregulating growth factors, particularly Vascular Endothelial Growth Factor (VEGF), which triggers angiogenesis (the formation of new blood vessels). This increased blood flow delivers vital nutrients to damaged tissues. Additionally, it promotes the expression of EGR-1 (Early Growth Response-1) and collagen, which are crucial for cellular migration and tissue reconstruction. It also interacts with the nitric oxide (NO) pathway, helping regulate vascular tone and protect mucosal linings.
What does research say about BPC-157?
Animal and in-vitro studies show remarkable tissue-healing acceleration. In rodent models, BPC-157 consistently heals Achilles tendons, collateral ligaments, and skeletal muscle transections. Human clinical trials remain extremely limited; however, pre-clinical safety profiles demonstrate low toxicity. Research also highlights strong cytoprotective properties, particularly in protecting the gastric mucosa against NSAID-induced damage and inflammatory bowel disease (IBD) symptoms in animal models.
Is BPC-157 FDA-approved or legally available?
In January 2025, the FDA placed BPC-157 on the Bulk Drug Substances Category 2 list, effectively restricting 503A compounding pharmacies from preparing it due to safety concerns and a lack of clinical trial data. It is currently classified as a 'research chemical' and is not approved for human clinical use, though it remains widely studied in pre-clinical settings.